Health Condition 1: null- Patients having classical signs and symptoms of Tamaka Shwasa(Bronchial Asthma)
Conditions
Interventions
Intervention1: Chandramrita Rasa: 375 mg twice with Honey orally for 28 Days
Control Intervention1: Not Applicable: Not Applicable
Sponsors
Institute for Post Graduate Teaching and Research in Ayurveda
Eligibility
Inclusion criteria
Inclusion criteria: 1.Both the sexes having age between 18 years to 60 years 2.Mild persistent cases of Bronchial Asthma with day time symptoms 3-6/week and nocturnal symptoms with 3-4/month. 3.Moderate persistence cases with daytime symptoms daily and nocturnal symptoms with one or more than one week but not more than 2 weeks.
Exclusion criteria
Exclusion criteria: 1.Age more than 60 years and below 18 years. 2.Mild intermittent, Moderated persistent, severe persistent to severe Asthma. 3.Dyspnoea resulting from other diseases like left ventricular failure, COPD (like Chronic Bronchitis, Emphysema), upper respiratory tract obstruction, bronchiectasis, cases of tuberculosis, interstitial lung disease/occupational lung disease, tropical pulmonary eosinophilia & allergic bronchopulmonary aspergillosis etc. 4.Patients having anaemia, pneumonia, tuberculosis, lung cancer, lung abscess and other such complicated conditions. 5.Patients having diabetes, hypertension, Chronic and Acute renal failure etc. conditions in which urination is markedly diminished or excessive were excluded. 6.HIV positive cases. 7.Pregnant/lactating mother. 8.Patients who need Salbutamol inhaler daily. 9.Patients having classical symptoms of Maha, Urdha, Chhinna and Kshudra Shwasa.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that the trial drugs will exert a significant action on Signs and Symptoms of Tamaka Shwasa. Improvement in AEC and other haematological (TLC, DLC, Hb, AEC), Peak Expiratory Flow Rate and Breath Holding Time.Timepoint: 18 Months | — |
Secondary
| Measure | Time frame |
|---|---|
| By providing better effect on Tamaka Shwasa, the drug will effect psychosomatic level of the enrolled patients, enhance quality of life and will contribute in reducing disability adjusted life years. Overall improvement in the disease condition, Quality of Life of the diseased. Based on the observations, the trial drug may be recommended to be added into the Essential Drugs List of Ministry of AYUSH, New DelhiTimepoint: 18 Months of Trial | — |
Countries
India
Contacts
Public ContactProf BJ Patgiri
Institute for Post Graduate Teaching and Research in Ayurveda Jamnagar
Outcome results
None listed